8-K: Celularity Invests in Defeye Amid Nasdaq Delisting Threat

Celularity Inc. acquired preferred stock in Defeye, Inc. for $2.89 million in product credits while simultaneously facing a Nasdaq delisting notice for failing to file its quarterly reports.

Summary

• Celularity Inc. entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. on August 5, 2025.
• Celularity acquired 7,198.630 shares of Defeye's Series Seed-2 Preferred Stock.
• The consideration for the shares was $2,890,250 in product purchase credits, pursuant to a supply and distribution agreement between Celularity and Defeye.
• On May 28, 2025, Celularity received a notice from Nasdaq regarding non-compliance with listing requirements due to the failure to timely file its quarterly report on Form 10-Q for the quarter ended March 31, 2025.
• Celularity submitted a plan to Nasdaq to regain compliance on August 1, 2025.
• Nasdaq granted Celularity an extension until August 31, 2025, to file its Form 10-Q for the periods ended March 31, 2025, and June 30, 2025.
• Failure to satisfy the terms of the exception will result in a written delisting notification from Nasdaq, which Celularity may appeal to a Hearings Panel.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the significant risk of Nasdaq delisting stemming from non-compliance with filing requirements. While there is a strategic investment, the immediate and severe nature of the compliance issue overshadows any potential positive impact from the investment.

Positives

• Strategic investment in Defeye, Inc. by acquiring Series Seed-2 Preferred Stock, potentially expanding Celularity's portfolio or market reach.
• The investment was made using product purchase credits, which could be a non-cash or advantageous use of existing assets for Celularity.

Negatives

• Received a notice of non-compliance from Nasdaq due to failure to timely file the Form 10-Q for the quarter ended March 31, 2025.
• Faces potential delisting from The Nasdaq Stock Market LLC if it fails to file the required Form 10-Q reports by August 31, 2025.

Risks

• Risk of delisting from Nasdaq, which could negatively impact stock liquidity and investor confidence.
• Failure to regain compliance with Nasdaq's timely filing criteria by the August 31, 2025 deadline.
• Potential for further regulatory scrutiny or penalties due to delayed financial reporting.
• The investment in Defeye, Inc. carries inherent risks associated with the performance and prospects of the acquired entity.

Future Outlook

Celularity's immediate future outlook is dominated by its efforts to regain compliance with Nasdaq's listing requirements by filing its overdue quarterly reports by August 31, 2025. Failure to meet this deadline could lead to delisting, though the company retains the right to appeal such a determination. The strategic investment in Defeye, Inc. represents a longer-term strategic move, but its impact on Celularity's near-term financial performance or stock price is secondary to the compliance issue.

Industry Context

The filing highlights two distinct aspects: a strategic investment and a regulatory compliance issue. The investment in Defeye, Inc. suggests Celularity is pursuing growth or diversification through M&A or strategic partnerships, a common trend in the biotechnology and healthcare sectors where companies seek to expand their pipeline or technology base. The Nasdaq non-compliance issue, however, is a significant concern, as timely financial reporting is a fundamental expectation for publicly traded companies across all industries. Such compliance failures can severely impact investor confidence and market valuation, particularly for smaller or emerging growth companies.

Corporate Governance

Legal Proceedings

• Initiation of Nasdaq's delisting process due to non-compliance with timely filing requirements, which could lead to formal delisting proceedings if the company fails to meet the extended deadline.

Stakeholder Impact

• Shareholders: Face significant uncertainty and potential loss of liquidity due to the risk of Nasdaq delisting. The value of their investment could be negatively impacted.
• Nasdaq: The company's non-compliance impacts Nasdaq's regulatory oversight and the integrity of its listing standards.
• Employees: Potential impact on employee morale and retention due to company's compliance issues and stock performance.

Next Steps

• File Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025, with Nasdaq by August 31, 2025, to regain compliance.
• Potentially appeal to a Nasdaq Hearings Panel if delisting notification is received.

Key Dates

Recommendation

The immediate and pressing concern is the Nasdaq delisting threat due to delayed financial filings. This creates significant uncertainty and downside risk for the stock. While the strategic investment in Defeye, Inc. could be a long-term positive, its impact is currently overshadowed by the compliance issues. A 'Hold' recommendation is appropriate as investors should monitor the company's ability to regain Nasdaq compliance. A failure to meet the August 31st deadline would likely lead to a 'Sell' recommendation, while successful compliance could shift the focus back to the company's underlying business and strategic initiatives.

Keywords

Celularity, Defeye, Nasdaq, Delisting, SEC Filing, 8-K, Preferred Stock, Investment, Financial Reporting, Compliance, Biotechnology